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Background
➢ SETD8 is the only methyltransferase
that is known to target and
monomethylate lysine 20 in histone
H4 (H4K20). H4K20 methylation by
SETD8 hinders DNA replication by
blocking acetylation in G1 phase,
suppresses p53 activation in cancer
cells, and SETD8 overexpression is
present in different cancers.
➢ There are limited known inhibitors
that bind to SETD8. Inhibitors may
bind to the cofactor, substrate, or
possible allosteric sites. Using the
“fragment drug discovery” method,
we are testing small compounds
(fragments) to structurally analyze
their binding mode to SETD8.
Combining these fragments that bind
in different sites of SETD8 could
lead to better inhibitors that may be
used in cancer treatments.

➢ The construct of SETD8 containing
the catalytic domain was used for
the study.

Results
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SETD8 overexpression in E. coli.
Nickel affinity and size exclusion
chromatography for purification

Protein crystallography and X-ray
diffraction for structures and find
binding location

➢ SETD8 activity was measured
using a bioluminescence assay
(MTase-GloTM, Promega), in which
the by-product SAH is converted
into ATP and is detectable by
luciferase reaction.
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UNC0379
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Figure 1. A and B correspond to two of
the strongest binding compounds used in
this study, these compounds were
provided by our collaborators3. C
corresponds to a confirmed binding
inhibitor that has been proven to have high
binding affinity to SETD81,2.
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Methods
Our collaborators used Differential
Scanning Fluorimetry (DSF) and
Surface plasmon resonance (SPR)
to screen a library of compounds
for possible binding inhibitors of
SETD8
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Figure 3. A- To get a more accurate reading
on our purified protein, we decided to take
fractions that came off a preparative sizing
column and put through an analytical
column. B- Known markers including
Myoglobin (17kD), γ-globulin (158kD), and
Thyroglobulin (670kD). C- Gel of purified
SETD8 determined to be a monomer with a
size of 18kD.

➢No apo-crystals were formed using
the long protein construct of SETD8.
We were successful in producing
crystals with protein and SAM
cofactor using a citrate salt after
screening hundreds of conditions
that included several salts, buffers,
and other precipitating agents.
A

Figure 4. Crystallization using condition
referred in Figure 3.B was used along
compound EML1046 (Figure 1.B). Results
were inconclusive because crystals did not
appear like the previous crystals.
Produced crystals were not useful in the
present form, we cannot confirm what the
crystals are, but they might contain the
binding compound tested.

Conclusions
➢ Further testing is required to know
the exact binding location of the
binding compounds.
➢ Using x-ray diffraction data from
SETD8 crystals, we can better
understand the binding location of
possible inhibitors. We can use this
data to modify the compounds in
the hopes that someday this
information may lead to cancer
treatment drugs.
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Figure 2. Different time plots were
measured after the second Ni column in a
Coomassie gel that showed the added Ni
His-tag being cut by a protease, leaving
only purified SETD8. SETD8 appeared in
the last lane between the 20kD-15kD
which is accurate to the molecular weight
of SETD8 (18743.13). The last band in the
gel indicates the cut His-tag that stayed
stuck in the column.

➢We obtained approximately 150
mg of purified protein from 2 L.
After purifying SETD8 using size
exclusion chromatography, we
tried growing protein crystals with
the purified protein under different
conditions.
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Gianluca Sbardella of Università
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